| 3DCRT | three-dimensional conformation radiation therapy |
| 5-FU | 5-fluorouracil |
| ABCG2 | ATP-binding cassette super-family G member 2 |
| AKT | protein kinase B |
| Arg | arginase |
| ATM | ataxia telangiectasia mutated |
| ATP | adenosine triphosphate |
| BED | biological equivalent dose |
| BRCA2 | breast cancer type 2 susceptibility protein |
| BR-PDAC | borderline resectable PDAC |
| CAF | cancer associated fibroblast |
| CCL2 | chemokine ligand 2 |
| CCR2 | C-C chemokine receptor type 2 |
| CDK4/6 | cyclin-dependent kinase 4 and 6 |
| CDKN2A | cyclin-dependent kinase inhibitor 2A |
| cGAS | cyclic GMP-AMP synthase |
| CRT | chemoradiotherapy |
| CSC | cancer stem cell |
| CSF1 | colony-stimulating factor |
| CSF1R | colony-stimulating factor 1 receptor |
| CT | chemotherapy |
| CTLA4 | cytotoxic T-lymphocyte associated protein 4 |
| CXCR4 | C-X-C motif chemokine receptor 4 |
| DAMPs | damage associated molecular patterns |
| DC | denditric cell |
| EGFR | epidermal growth factor receptor |
| EMT | epithelial to mesenchymal transition |
| EORTC | European organisation for research and treatment of cancer |
| ERK | mitogen-activated protein kinase 1 |
| ESPAC | European study group for pancreatic cancer |
| EV | extracellular vesicle |
| FLASH RT | ultrahigh dose-rate radiation therapy |
| GIST | gastrointestinal study group |
| HIF-1α | hypoxia inducible factor 1 |
| HMGB-1 | high mobility group box 1 |
| HR | homologous recombination |
| ICD | immunogenic cell death |
| IFN-γ | interferon-γ |
| IMRT | intensity modulated radiation therapy |
| iNOS | inducible nitric oxide synthase |
| KRAS | kirsten rat sarcoma |
| LA-PDAC | locally advanced PDAC |
| LET | linear energy transfer |
| LPS | lipopolysaccharide |
| MDSC | myeloid-derived suppressor cells |
| MEK | mitogen-activated protein kinase kinase |
| MHC 1 | major histocompatibility complex class 1 |
| mTOR | mammalian target of rapamycin |
| nab-paclitaxel | nanoparticle-bound paclitaxel |
| NF-κB | nuclear factor kappa B |
| NHEJ | non homologous end joining |
| NRF2 | nuclear factor erythroid 2-related factor 2 |
| OAR | organ at risk |
| OS | overall survival |
| PARP | poly(ADP-ribose) polymerase |
| PDAC | pancreatic ductal adenocarcinoma |
| PD1 | programmed cell death 1 |
| PDK1 | pyruvate dehydrogenase kinase 1 |
| PD-L1 | programmed cell death ligand 1 |
| PDX | patient-derived xenograft |
| PI3K | phosphatidylinositol 3-kinase |
| POLO | pancreas cancer olaparib ongoing |
| PREOPANC | preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer |
| PRODIGE | trial comparing adjuvant chemotherapy with gemcitabine versus mfolfirinox to treat resected pancreatic adenocarcinoma |
| PT | proton therapy |
| RAF | rapidly accelerated fibrosarcoma |
| RAS | rat sarcoma |
| RBE | relative biological effectiveness |
| ROS | reactive oxygen species |
| R-PDAC | resectable PDAC |
| RT | radiotherapy |
| RTOG | radiation therapy oncology group |
| SBRT | stereotactic body radiation therapy |
| SDF-1 | stromal derived factor 1 |
| SMAD4 | mothers against decapentaplegic homolog 4 |
| SMART | stereotactic magnetic resonance guide adaption radiation therapy |
| SPArc | continuous spot-scanning protons arc |
| STING | stimulator of interferon genes |
| TAM | tumour-associated macrophages |
| TGFβ | transforming growth factor beta |
| TIL | tumour infiltrating lymphocytes |
| TNF | tumour necrosis factor |
| TRAIL | TNF-related apoptosis-inducing ligand |
| Trex1 | three prime repair exonuclease 1 |
| UPR | unfolded protein response |
| VEGF | vascular endothelial growth factor |
| Wnt | wingless-integration-1 |
| ZEB | zinc finger E-box binding homeobox |